Ranjbar Elham, Shams Jamal, Sabetkasaei Masoumeh, M-Shirazi Minoo, Rashidkhani Bahram, Mostafavi Ali, Bornak Eiliyaz, Nasrollahzadeh Javad
Nutr Neurosci. 2014 Feb;17(2):65-71. doi: 10.1179/1476830513Y.0000000066. Epub 2013 Nov 26.
Zinc is found in abundance in the human brain. Patients with depression may have decreased consumption of food sources rich in zinc, and zinc supplementation may have a potential influence on depressive symptoms. However, clinical trials on the effect of zinc supplementation in depression are limited. The objective of the present study was to determine the effect of zinc supplementation on efficacy of antidepressant therapy. Furthermore, the effect of zinc on plasma levels of interleukin-6 (IL-6), tumor necrosis factor (TNF-α), and brain-derived neurotrophic factor-a (BDNF-a) were assessed.
A single-center, randomized, double-blind, placebo-controlled trial of zinc supplementation was conducted in patients with DSM-IV major depression. Forty-four patients of both sexes aged 18-55 years were recruited for this study from a university hospital. The zinc-supplemented group received zinc sulfate (25 mg elemental Zn/day) orally in addition to their selective serotonin reuptake inhibitor antidepressants for 12 weeks. Symptoms were evaluated using the Hamilton Depression Rating Scale (HDRS) on arrival, weeks 6 and 12. Plasma levels of IL-6, TNF-α and BDNF-a were measured at baseline and at the end of study.
Twenty patients in zinc group and 17 patients in placebo groups completed the study. At baseline, there were no significant differences in any variable between the patients allocated to receive placebo and those taking zinc supplement. Zinc supplementation significantly reduced HDRS compared to placebo (P < 0.01 at 12th week). No significant differences were observed in plasma levels of IL-6, TNF-α, and BDNF-a between zinc-supplemented and placebo-supplemented group.
Zinc supplementation in conjunction with antidepressant drugs might be beneficial for reducing depressive symptoms. However, its effect does not appear to be mediated through impact of zinc on inflammatory processes.
锌在人脑中大量存在。抑郁症患者可能减少了富含锌的食物来源的摄入,补充锌可能对抑郁症状有潜在影响。然而,关于补充锌对抑郁症影响的临床试验有限。本研究的目的是确定补充锌对抗抑郁治疗疗效的影响。此外,还评估了锌对白细胞介素-6(IL-6)、肿瘤坏死因子(TNF-α)和脑源性神经营养因子-a(BDNF-a)血浆水平的影响。
对符合DSM-IV重度抑郁症的患者进行了一项单中心、随机、双盲、安慰剂对照的锌补充试验。从一家大学医院招募了44名年龄在18至55岁之间的男女患者参与本研究。锌补充组除服用选择性5-羟色胺再摄取抑制剂抗抑郁药外,还口服硫酸锌(25毫克元素锌/天),持续12周。在入组时、第6周和第12周使用汉密尔顿抑郁量表(HDRS)评估症状。在基线和研究结束时测量IL-6、TNF-α和BDNF-a的血浆水平。
锌组20名患者和安慰剂组17名患者完成了研究。在基线时,分配接受安慰剂的患者和服用锌补充剂的患者之间在任何变量上均无显著差异。与安慰剂相比,补充锌显著降低了HDRS(第12周时P<0.01)。补充锌组和补充安慰剂组之间在IL-6、TNF-α和BDNF-a的血浆水平上未观察到显著差异。
补充锌联合抗抑郁药物可能有助于减轻抑郁症状。然而,其作用似乎不是通过锌对炎症过程的影响来介导的。